Head-To-Head Review: Vireo Growth (VREOD) & Its Peers

Vireo Growth (OTCMKTS:VREOD) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Vireo Growth to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, risk, institutional ownership and valuation.

Risk & Volatility

Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s competitors have a beta of -3.79, suggesting that their average stock price is 479% less volatile than the S&P 500.

Institutional and Insider Ownership

32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Vireo Growth shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Vireo Growth and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$3.53 billion	$3.17 billion	552.64

Vireo Growth’s competitors have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Vireo Growth and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,380.61%	-219.90%	-15.56%

Analyst Ratings

This is a summary of current ratings and price targets for Vireo Growth and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7806	13897	25803	1039	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.32%. Given Vireo Growth’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its competitors.

Summary

Vireo Growth competitors beat Vireo Growth on 9 of the 13 factors compared.

Vireo Growth Company Profile

Vireo Growth Inc. is a cannabis company focused on the cultivation, processing, manufacturing and sale of medical and adult-use cannabis products in the United States. Its product portfolio includes cannabis flower, pre-rolls, concentrates, edibles and other branded cannabis products, depending on the regulations and operating licenses in each market. The company has operated a vertically integrated business model that combines cannabis production with retail distribution through dispensaries, including locations operating under the Green Goods brand.